Hi thoth2 Not at all I want this to do well believe me. Just been stung by another share that has a few similarities to sar and am getting twitchy. We've had so much good news recently I figured the sp would be in the 2's by now at least? I really appreciate your posts so thanks for that. I will keep the negative posts to myself from now on. Gl
personally. a lot of it is still early science. CAR-T and immunotherapy getting lots of trial flops. but early research interesting. Tyk2 inhibition look sto have a role in preventing alzheimers. (but early research stage still). Little known fact. no one who smokes gets parkinsons (very cheap preventative measure is 20 bensons a day). Combo therapies are great. segements the market into effective niches (Sierra is doing that with Chk1, awaiting announcement imminently on which combos, and John currentlt doing combo assessment on Tyk2 (afgaian awaiting announcement on pre clinical results). its the way to go..
Hi all, there seems to be a lot of news around at the moment (on the tv) around advances in treatment of cancer (t_cells) and news again yesterday about huge advances in treatments (combo of 2 existing drugs) in curing alzheimers and parkinsons.
I just wondered if a) SAR can take advantage of current interest. B) do the advances in treatment help / hinder the work SAR are doing. Clearly if cures are established before SAR get product to market our product becomes less valued.
Obviously all advance on these terrible illnesses is fantastic, but I am just interested to hear views of you guys, as I am not an expert.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.